NAUT vs PATH · $103.4M cap vs P/E 19, rev $1.61B
Nautilus Biotechnology Inc (NAUT) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Nautilus Biotechnology Inc (NAUT) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
NAUT does not have a complete income-statement cache yet.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
NAUT currently screens at market cap $103.4M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the NAUT and PATH stock pages for the full models.
Not investment advice.